IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor conferences:

  • Stifel 2019 Healthcare Conference on Tuesday, November 19 at 4:45 p.m. ET in New York.
  • Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 11:20 a.m. GMT in London.
  • Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4 at 3:00 p.m. ET in New York.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences Announces Third Quarter 2019 Financial Results

MOUNTAIN VIEW, Calif.,  — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced its financial results for the third quarter ended September 30, 2019 and provided an update on recent developments.

“During the third quarter of 2019, we continued to make progress towards our research, clinical development and financing goals, including initiating our first-in-human clinical trial of our lead IgM antibody, IGM-2323, in patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma and closing both our Series C financing and our initial public offering,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “During 2020, we hope to continue our progress and report initial data from our IGM-2323 Phase 1 trial and file an IND for our second product candidate, an IgM antibody targeting DR5.”

Recent Highlights

Initiated Phase 1 clinical trial of IGM-2323. In October 2019, IGM announced dosing of the first patient in its Phase 1 clinical trial evaluating IGM-2323 in patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL). This Phase 1 clinical trial represents the first-in-human application of IGM Biosciences’ engineered IgM antibody technology. The Company expects to report initial data from this Phase 1 trial in the second half of 2020.

Completed initial public offering (IPO) and Series C financing. In September 2019, IGM closed its IPO of 12,578,125 shares of its common stock at a price to the public of $16.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 1,640,625 additional shares. IGM received gross proceeds of $201.3 million from the offering. Prior to the IPO, in July 2019, IGM completed a $102 million Series C financing which included conversion of $20 million in unsecured promissory notes. In aggregate, IGM raised $264.5 million in cash proceeds pursuant to these financings, net of note conversion, underwriting discounts and commissions and estimated offering expenses.

Third Quarter 2019 Financial Results

Cash and Investments: Cash and investments as of September 30, 2019 were $251.3 million.
Research and Development (R&D) Expenses: For the third quarter of 2019, R&D expenses were $8.3 million.
General and Administrative (G&A) Expenses: For the third quarter of 2019, G&A expenses were $2.4 million.
Net Loss: For the third quarter of 2019, net loss was $10.2 million, or a loss of $2.41 per share.
Shares outstanding: Shares outstanding as of September 30, 2019 were 30.5 million including both voting common stock and non-voting common stock.

Financial Guidance

Management estimates operating expenses for 2019 of approximately $42.0 – $45.0 million, including estimated stock-based compensation expense of approximately $1.0 million. Management also expects a balance of over $230 million in cash and investments and approximately 30.6 million shares outstanding, including both voting common stock and non-voting common stock, at December 31, 2019.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or IGM Biosciences’ future financial or operating performance. Such forward-looking statements include, but are not limited to, statements regarding the Company’s Phase 1 clinical trial of IGM-2323, the potential of, and expectations regarding, the Company’s IgM technology platform, the timing of reporting initial data from the IGM-2323 Phase 1 clinical trial, the timing of filing an IND for the Company’s second product candidate, estimated 2019 operating expenses and stock-based compensation expense, estimated balance of cash and investments and number of shares outstanding as of December 31, 2019, and statements by the Company’s Chief Executive Officer. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: IGM Biosciences’ ability to accurately forecast financial results; IGM Biosciences’ early stages of clinical drug development; uncertainties related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM Biosciences’ ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; IGM Biosciences’ ability to adequately demonstrate sufficient safety and efficacy of its product candidates; IGM Biosciences’ ability to enroll patients in its ongoing and future clinical trials; IGM Biosciences’ ability to successfully manufacture and supply its product candidates for clinical trials; IGM Biosciences’ ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM Biosciences is targeting; IGM Biosciences’ ability to obtain, maintain, and protect its intellectual property rights; developments relating to IGM Biosciences’ competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in IGM Biosciences’ filings with the Securities and Exchange Commission (“SEC”), including IGM Biosciences’ Quarterly Report on Form 10-Q filed with the SEC on November 7, 2019 and in IGM Biosciences’ future reports to be filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM Biosciences specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma

MOUNTAIN VIEW, Calif., Oct. 02, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-2323, the Company’s CD20 x CD3 bispecific IgM antibody, in patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL).

This Phase 1 clinical trial represents the first in-human application of IGM Biosciences’ engineered IgM antibody technology. The Phase 1 multi-center, open label trial is intended to assess the safety, pharmacokinetics and preliminary efficacy of intravenous IGM-2323 in patients with relapsed/refractory B cell NHL. IGM-2323 will initially be administered at a planned fixed-dose, as part of a dose escalation protocol.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or IGMBiosciences’ future financial or operating performance. Such forward-looking statements include, but are not limited to, statements regarding the Company’s Phase 1 clinical trial of IGM-2323. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to:  IGM Biosciences’ early stages of clinical drug development;  uncertainties related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM Biosciences’ ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; IGM Biosciences’ ability to adequately demonstrate sufficient safety and efficacy of its product candidates; IGM Biosciences’ ability to enroll patients in its ongoing and future clinical trials; IGM Biosciences’ ability to successfully manufacture and supply its product candidates for clinical trials; IGM Biosciences’ ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM Biosciences is targeting; IGM Biosciences’ ability to obtain, maintain, and protect its intellectual property rights; developments relating to IGM Biosciences’ competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in IGM Biosciences’ filings with the Securities and Exchange Commission (“SEC”), including IGM Biosciences’ prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, dated September 17, 2019 and in  IGM Biosciences’ future reports to be filed with the SEC.  Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM Biosciences specifically disclaims any obligation to update any forward-looking statement, except as required by law.

CONTACT

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Sept. 20, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the closing of its initial public offering of 12,578,125 shares of its common stock at a price to the public of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,640,625 additional shares. The shares began trading on The Nasdaq Global Select Market on September 18, 2019 under the symbol “IGMS.” IGM received gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $201.3 million.

Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.

A registration statement relating to the offering was declared effective by the United States Securities and Exchange Commission on September 17, 2019. The offering was made only by means of a prospectus. A copy of the final prospectus relating to this offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@pjc.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, by telephone at (212) 518-9658 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences Announces Pricing of Initial Public Offering

September 17, 2019 at 8:46 PM EDT

MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the pricing of its initial public offering of 10,937,500 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market on September 18, 2019 under the symbol “IGMS.” The offering is expected to close on September 20, 2019, subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by IGM, are expected to be approximately $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,640,625 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Jefferies, Piper Jaffray, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.

A registration statement relating to the offering has been filed with the United States Securities and Exchange Commission and was declared effective on September 17, 2019. The offering is made only by means of a prospectus. When available, a copy of the prospectus relating to this offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@pjc.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, by telephone at (212) 518-9658 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

CONTACT:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, today announced the closing of its $102 million Series C financing. New investors included Redmile Group, Janus Henderson Investors, Vivo Capital and another large U.S.-based, healthcare-focused fund. Haldor Topsøe Holding A/S, which has funded IGM since 2010, also participated in the round.

“We are very pleased to have the support of these sophisticated healthcare-focused investors,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “We look forward to working with them to realize the potential of our IgM platform to deliver new therapeutic treatments to patients with cancer.”

Proceeds from this financing will be used to advance the Company’s IgM platform technology and its proprietary oncology pipeline, including its lead program, a CD20 x CD3 bispecific antibody, which is expected to enter the clinic later this year.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that is focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies, and IGM believes it has the most advanced research and development program focused on engineered IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent advantages may provide superior performance, as compared to IgG antibodies. For more information about IGM Biosciences, its technologies and its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of M. Kathleen Behrens, Ph.D., to its Board of Directors. Dr. Behrens has been a pioneer in the biotech industry throughout her career, beginning as an equity research analyst at Robertson Stephens & Co. She has been an industry leader in a wide variety of roles, including equity research analyst, venture capital investor, public equity investor, entrepreneur, executive, director and public policy and industry trade group committee member.

Dr. Behrens currently serves as the Chair of the Board of Directors of Sarepta Therapeutics, Inc. and has been a member of its Board since 2009.

“Kathy brings a unique perspective to IGM’s Board – one that has been shaped by a successful career as an entrepreneur, company founder, private and public investor, director, public policy expert and management advisor across the life sciences industry. IGM is honored to have her join us at this exciting point in our development,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Importantly, Kathy has first-hand experience guiding an antibody platform company from its inception as a privately held entity to a successful publicly traded company with a deep pipeline. Kathy’s financial industry experience also adds a key perspective to our Board as we look to build our infrastructure and strategy for 2019 and beyond. We are very pleased that Kathy will be joining the Company, and IGM will benefit greatly from her counsel and experience.”

“IGM is looking to unlock the inherent advantages that IgM antibodies may have over currently available IgG antibody treatments. It is the ingenuity and passion of companies like IGM that has excited and engaged me in this industry for the past 35 years, and it is why I remain a steadfast believer in its ability to evolve, innovate and create new products for the treatment of life-threatening human diseases,” commented Dr. Behrens. “I look forward to working with IGM, and I am very excited by the prospect of witnessing its progress firsthand.”

Dr. Behrens played an important role in the founding of one of the seminal antibody platform companies, Protein Design Labs, Inc. She also served as a director of the groundbreaking antibody platform company, Abgenix, Inc., from the company’s early rounds of private financings through its sale to Amgen Inc. Dr. Behrens also served as a director of Amylin Pharmaceuticals, Inc. from 2009 until its sale to Bristol-Myers Squibb Company.

Dr. Behrens serves as a member of the Steering Committee of the Coalition for 21st Century Medicine, of which she was a co-founder. She has served as a member of the President’s Council of Advisors on Science and Technology (“PCAST”) and as chairwoman of PCAST’s subcommittee on Personalized Medicine. She has been a director on the Board on Science, Technology and Economic Policy of the National Research Council and has also served as a director, president and chairwoman of the National Venture Capital Association.

Dr. Behrens began her career in the financial services industry as an equity research analyst with Robertson Stephens & Co., where she became a general partner, managing director and venture capital investor. Dr. Behrens continued in her venture capital management capacity as a general partner for selected venture funds of RS Investments after a management-led buyout of the firm from Bank of America Corporation.

Dr. Behrens holds a Ph.D. in Microbiology from the University of California, Davis.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience 

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Misbah Tahir to the newly created position of Chief Financial Officer. Mr. Tahir joins IGM with more than twenty years of experience in finance and strategic planning, including public market financings and product launches. Most recently, Mr. Tahir was Vice President, Head of Finance at Dermira, Inc., where he helped build the finance, treasury, accounting and SEC compliance and reporting functions during a period of rapid growth, and played an integral role in the company’s initial public offering and follow-on public financings.

“We are very pleased that Misbah has decided to join the IGM team, and his skills and leadership will be pivotal to the development of our financial infrastructure, capabilities and strategy at this exciting time in our growth as a company,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “His experience in building finance and accounting organizations, managing financial and strategic planning processes and interfacing with the biotechnology capital markets will be critical to IGM as we move a potentially transformative new therapeutic approach toward clinical proof of concept studies and eventual market launch.”

“IGM is pioneering an entirely new class of therapeutic drugs for the treatment of cancer and other serious diseases through its proprietary IgM antibody technology,” added Mr. Tahir. “The potential of this platform and the inspired, passionate and determined environment that defines IGM drew me to this opportunity. I am excited to become part of this experienced team that is devoted to delivering important advances in antibody-based therapies and the treatment of urgent unmet medical needs.”

During his career in the biotechnology industry, Mr. Tahir has helped finance, advance and launch multiple new therapeutic drugs. While at Dermira, Mr. Tahir was a key member of the financing team, which raised over $750 millionto advance the company’s clinical programs and corporate development, and he was a leader in Dermira’s transition to a commercial-stage company.

Prior to his role at Dermira, Mr. Tahir was Director, Head of Commercial Financial Planning and Analysis at Onyx Pharmaceuticals, Inc., where he served as finance business partner to the Chief Commercial Officer during the U.S. and international launches of Kyprolis® for multiple myeloma and was responsible for the financial planning processes across Onyx’s product portfolio supporting annual product sales in excess of $1 billion. Before that, he was Associate Director of Revenue at Human Genome Sciences, Inc. (HGS), where he led all revenue and collaboration accounting activities during the U.S. launch of Benlysta® and was Chair of the HGS-GlaxoSmithKline Joint Finance Committee.

Prior to HGS, Mr. Tahir spent six years at Amgen, Inc. in finance and accounting management roles. He began his professional career at the global management consulting firm Oliver Wyman, where he developed business development and market-entry strategies for diverse clients.

Mr. Tahir received an MBA from the University of Michigan Business School and a BA from the University of Pennsylvania.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases since 2010. IGM Biosciences is working to develop IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins Chief Medical Officer, Daniel S. Chen, M.D., Ph.D., to Build IGM’s Clinical Development Function

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Wayne Godfrey, M.D. to the newly created position of Vice President, Clinical Development.

Dr. Godfrey will help lead global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 25 years of experience in cancer immunology and immunotherapy research and development, most recently with Kite/Gilead, where he led the CAR-T CD19-directed pivotal Phase II study, ZUMA-5.

“Wayne has been a pioneer in the field of immuno-oncology, including leading the team that first identified human OX40 and OX40-Ligand with Dr. Edgar G. Engleman at Stanford, and he played an important role in the identification, culture, and characterization of human T regulatory cells at the University of Minnesota, in collaboration with Dr. Bruce R. Blazar. Wayne was an inventor on some of the seminal patents licensed in these fields, and I am honored to have the opportunity to work directly with him,” said Daniel S. Chen, Chief Medical Officer of IGM Biosciences. Dr. Chen continued, “Wayne’s scientific immuno-oncology and clinical hematology experience, combined with his proven leadership abilities as past Chief Medical Officer at Bavarian-Nordic Immunotherapeutics and Etubics, provides IGM with valuable new expertise and know-how as we build IGM’s clinical development capabilities.”

“Wayne’s experience with CAR-T approaches to lymphoma and diverse approaches to cancer immunotherapy in solid tumors will provide strong support for the development of our industry-leading IgM technology platform,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

Dr. Godfrey commented: “I’m fascinated by IGM’s innovative and proprietary engineering approach to bispecific antibodies, which offers many new avenues for creating the next generation of therapeutics for immuno-oncology and beyond. The ability to target cancer antigens that elude IgG-based therapeutics and the framework for adding multiple additional binding domains and payloads are very compelling. Importantly, the ability of multivalent IgM antibodies to powerfully stimulate signaling receptors may also enable us to realize the true potential of OX40 and other TNFr family members as immuno-oncology targets. I’m very excited to have the opportunity to study and develop the potential of IGM’s technology in the clinic.”

Dr. Godfrey conducted research and studied clinical immunology at Stanford, and then went on to run his own lab as a faculty member in Hematology, Oncology and Transplantation at the University of Minnesota and developed and patented methods to purify and culture T regulatory cells. His biotech and pharma experience has included work on antigen presenting cell vaccines, TLR agonists, and viral-prime boost vaccines in both research and global clinical development roles. Subsequently, he also served as the medical lead for multiple clinical studies of Idelalisib in lymphoma (Phase 1-4) and contributed to the filing and FDA approval of Zydelig® at Gilead Sciences. After working on CEA and HER2 targeted adenoviral cancer vaccines at Etubics/Nantcell, he most recently was the clinical development lead for anti-CD19 directed CAR-T cell studies in follicular lymphoma at Kite/Gilead.

Dr. Godfrey has co-authored multiple clinical and scientific publications, including “Identification of a human OX40 ligand, a costimulatory of CD4+ T cells with homology to tumor necrosis factor,” and “PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma,” published in The New England Journal of Medicine. He is also an inventor or co-inventor on multiple patents, including “Regulatory T cells (CD4+CD25+) and their use in immunotherapy.” Dr. Godfrey earned an M.D. from Washington University and completed his internal medicine residency and Clinical Immunology, Hematology and Bone Marrow Transplantation Fellowships at Stanford University.

Dr. Chen and Dr. Godfrey will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. Dr. Chen joined IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts